用于治疗日本慢性乙型肝炎病毒感染患者的核苷酸（t）类似

StephenW

J Med Virol. 2019 Nov 28. doi: 10.1002/jmv.25644. [Epub ahead of print]
Significance of switching of the nucleos(t)ide analog used to treat Japanese patients with chronic hepatitis B virus infection from entecavir to tenofovir alafenamide fumarate.
Uchida Y1, Nakao M1, Tsuji S1, Uemura H1, Kouyama JI1, Naiki K1, Motoya D1, Sugawara K1, Nakayama N1, Imai Y1, Tomiya T1, Mochida S1.
Author information

1
    Department of Gastroenterology & Hepatology, Faculty of Medicine, Saitama Medical University.

Abstract
BACKGROUNDS:

The significance of switching of the nucleos(t)ide analog used to treat patients with HBV from entecavir (ETV) to tenofovir alafenamide fumarate (TAF) is uncertain.
METHODS:

The subjects were 159 patients with HBV who received treatment with ETV followed by TAF. Among them, the serial changes in the HBV marker levels were monitored in the 92 patients in whom the serum HBsAg levels were ≥100 IU/mL during the 48-week period immediately before and after the switching. A questionnaire survey for medication compliance was performed in 127 patients.
RESULTS:

The serum HBsAg levels (Log IU/mL) decreased by 0.041 during the ETV treatment period and by 0.068 during the TAF administration period. The degree of reduction was higher during the TAF administration period than during the ETV administration period in patients without cirrhosis (P=0.030), patients with genotype B HBV (P=0.014), and patients with undetectable serum HBcrAg (P=0.038). Multivariate analysis revealed that the HBV genotype (B vs. C; OR 3.400, P=0,025) and serum AST level (every 1+; 1.111, P=0.015) at the time of switching as factors influencing the treatment efficacy. Thirty-six patients (28%) answered that the number of days that they forgot to take the drug decreased after the drug switching, and 77 patients (61%) reported feeling satisfied with the drug switching.
CONCLUSION:

Switching of the nucleos(t)ide analog used from ETV to TAF may be useful in the treatment of patients with HBV infection, as it is associated with both decrease of the serum HBsAg level and improvement of the medication compliance. (249 words) This article is protected by copyright. All rights reserved.

This article is protected by copyright. All rights reserved.
KEYWORDS:

HBs-antigen; entecavir; medication compliance; tenofovir alafenamide fumarate

PMID:
    31777965
DOI:
    10.1002/jmv.25644

StephenW

J Med Virol。 2019年11月28日.doi：10.1002 / jmv.25644。 [Epub提前发布]
用于治疗日本慢性乙型肝炎病毒感染患者的核苷酸（t）类似物从恩替卡韦转用替诺福韦阿拉芬酰胺富马酸酯的意义。
内田Y1，中尾M1，ji S1，上村H1，尾山JI1，内木K1，本屋D1，gawa原K1，中山N1，今井Y1，富谷T1，内田S1。
作者信息

1个
Sa玉医科大学医学院消化病学和肝病学系。

抽象
背景：

恩替卡韦（ETV）改用替诺福韦阿拉芬酰胺富马酸酯（TAF）来治疗HBV患者的核苷酸（t）类似物转换的重要性尚不确定。
方法：

受试者为159例接受ETV和TAF治疗的HBV患者。其中，在切换前后48周内，对92例血清HBsAg≥100 IU / mL的患者进行了HBV标记水平的连续监测。对127名患者进行了药物依从性问卷调查。
结果：

在ETV治疗期间，血清HBsAg水平（Log IU / mL）下降0.041，在TAF给药期间下降0.068。在没有肝硬化的患者（P = 0.030），基因型B HBV的患者（P = 0.014）和血清HBcrAg不能检测的患者中，TAF给药期间的降低程度高于ETV给药期间（P = 0.038）。多变量分析显示，切换时的HBV基因型（B vs. C； OR 3.400，P = 0.025）和血清AST水平（每1+； 1.111，P = 0.015）是影响治疗效果的因素。三十六名患者（28％）回答说，他们在换药后忘记服药的天数减少了，而77名患者（61％）表示对换药感到满意。
结论：

从ETV转换为TAF的核苷酸（t）类似物可能对治疗HBV感染的患者有用，因为它与血清HBsAg水平降低和药物依从性改善有关。 （249个字）本文受版权保护。版权所有。

本文受版权保护。版权所有。
关键字：

HBs抗原；恩替卡韦用药依从性；替诺福韦阿拉芬酰胺富马酸酯

PMID：
31777965
DOI：
10.1002 / jmv.25644